The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
Open accessAbstract
Summary: Romiplostim was effective, safe, and well‐tolerated over 6–12 months of continuous treatment in Phase 3 trials in patients with immune thrombocytopenia ( ITP ). This report describes up to 5 years of weekly treatment with romiplostim in 292 adult ITP patients in a long‐term, single‐arm, open‐label study. Outcome measures included adverse events (including bleeding, thrombosis, malignancy, and reticulin/fibrosis), platelet response (platelet count >50 × 10 9 per litre), and the proportion of patients requiring rescue treatments. Treatment–related serious adverse events were infrequent and did not increase with longer treatment. No new classes of adverse events emerged. Thrombotic events occurred in 6·5% of patients and were not associated with platelet count. Median platelet counts of 50–200 × 10 9 per litre were maintained with stable doses of romiplostim (mean 5–8 μg/kg; generally self‐administered at home) throughout the study. A platelet response was achieved at least once by 95% of patients, with a platelet response maintained by all patients on a median 92% of study visits. There was a low rate of bleeding and infrequent need for rescue treatments. In conclusion, this study demonstrated that romiplostim was safe and well‐tolerated over 614 patient‐years of exposure in ITP patients, and that efficacy was maintained with stable dosing for up to 5 years of continuous treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Provan, D., Stasi, R., Newland, A. C., Blanchette, V. S., Bolton-Maggs, P., Bussel, J. B., Chong, B. H., Cines, D. B., Gernsheimer, T. B., Godeau, B., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225565 · Cited by 2,271
Self-citationNeunert, C., Lim, W., Crowther, M., Cohen, A., Solberg, L., & Crowther, M. A. (2011) · Blood · doi:10.1182/blood-2010-08-302984 · Cited by 1,856
Kuter, D. J., Bussel, J. B., Lyons, R. M., Pullarkat, V., Gernsheimer, T. B., Senecal, F. M., Aledort, L. M., George, J. N., Kessler, C. M., Sanz, M. A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60203-2 · Cited by 867
Self-citationThrombocytopenia caused by the development of antibodies to thrombopoietin
Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., & Kuter, D. J. (2001) · Blood · doi:10.1182/blood.v98.12.3241 · Cited by 683
Self-citationBussel, J. B., Provan, D., Shamsi, T., Cheng, G., Psaila, B., Kovaleva, L., Salama, A., Jenkins, J. M., Roychowdhury, D., Mayer, B., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60402-5 · Cited by 539
Self-citationMcMillan, R., Wang, L., Tomer, A., Nichol, J. L., & Pistillo, J. (2003) · Blood · doi:10.1182/blood-2003-08-2672 · Cited by 537
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
Bussel, J. B., Kuter, D. J., George, J. N., McMillan, R., Aledort, L. M., Conklin, G. T., Lichtin, A. E., Lyons, R. M., Nieva, J., Wasser, J. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054626 · Cited by 530
Self-citationRomiplostim or Standard of Care in Patients with Immune Thrombocytopenia
Kuter, D. J., Rummel, M., Boccia, R., Macik, B. G., Pabinger, I., Selleslag, D., Rodeghiero, F., Chong, B. H., Wang, X., & Berger, D. P. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002625 · Cited by 427
Self-citationChang, M., Nakagawa, P. A., Williams, S. A., Schwartz, M. R., Imfeld, K. L., Buzby, J. S., & Nugent, D. J. (2003) · Blood · doi:10.1182/blood-2002-05-1475 · Cited by 392
Thrombopoietin and Thrombopoietin Mimetics in the Treatment of Thrombocytopenia
Kuter, D. J. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.042307.181154 · Cited by 180
Self-citation
Cited by
Cooper, N., & Ghanima, W. (2019) · New England Journal of Medicine · doi:10.1056/nejmcp1810479 · Cited by 503
Thrombopoietin receptor agonists: ten years later
Ghanima, W., Cooper, N., Rodeghiero, F., Godeau, B., & Bussel, J. B. (2019) · Haematologica · doi:10.3324/haematol.2018.212845 · Cited by 416
Self-citationNeunert, C., Noroozi, N., Norman, G., Buchanan, G. R., Goy, J., Nazi, I., Kelton, J. G., & Arnold, D. M. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12813 · Cited by 338
Fostamatinib for the treatment of chronic immune thrombocytopenia
Connell, N. T., & Berliner, N. (2019) · Blood · doi:10.1182/blood-2018-11-852491 · Cited by 108
Metadata
- Authors
- Kuter, D. J., Bussel, J. B., Newland, A., Baker, R. I., Lyons, R. M., Wasser, J., Viallard, J., Macik, G., Rummel, M., Nie, K., & Jun, S.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2013-02-22
- Volume
- 161
- Issue
- 3
- Pages
- 411-423
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2033207183
- Cited by
- 275
- References
- 12
- FWCI
- 19.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. https://app.cochat.ai/papers/10.1111/bjh.12260
- The paper
- Kuter, D. J., Bussel, J. B., Newland, A., Baker, R. I., Lyons, R. M., Wasser, J., Viallard, J., Macik, G., Rummel, M., Nie, K., & Jun, S. (2013). Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. British Journal of Haematology. https://doi.org/10.1111/bjh.12260
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.